RxDoctor Payments Data

Nauman Taj, MD

Psychiatry · Fort Collins, CONPI 1942516539

Payments from drug & device makers

What this record shows

16 manufacturers reported payments, led by AbbVie at 57.1% of the total. 2025 is the largest year on record at $5,245, more than ten times the $468 reported in 2019. Among psychiatry clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,909in general payments, 2019–2025

Across 140 payments — averaging $63.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • Neurocrine Biosciences, Inc.$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$609
  • Otsuka America Pharmaceutical, Inc.$381
  • Alkermes, Inc.$332
  • Teva Pharmaceuticals USA, Inc.$288
  • plus $987 from 10 others

What the payments were for

  • Speaking & faculty fees$4,50051%
  • Food & beverage$4,40949%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,909 in reported general payments places this provider in the 95th percentile of 559 psychiatry providers in Colorado.

See all psychiatry providers in Colorado

Medicare billing

Part B allowed, 2024
$15,480
Medicare patients
36
Services billed
172

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate14$113,625
NuedextaDextromethorphan Hbr/Quinidine13$19,739
Clozapine123$10,439
Chlorpromazine Hcl31$9,544
Divalproex Sodium ErDivalproex Sodium43$5,861
Valproic AcidValproic Acid (As Sodium Salt)47$4,972
Aripiprazole93$4,843
Lamotrigine198$2,555
Duloxetine Hcl71$2,524
Olanzapine84$2,379
Lurasidone Hcl27$2,029
Atropine Sulfate37$1,765
Divalproex Sodium51$1,554
Naltrexone Hcl14$1,244
Quetiapine Fumarate51$942

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$1,226$113,62514 claims
Avanir Pharmaceuticals, Inc.Nuedexta$19$19,73913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 559 psychiatry providers in Colorado.

Other psychiatry in Fort Collins

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →